- AbbVie will invest $380 million to build two new active pharmaceutical ingredient (API) manufacturing facilities at its North Chicago, Illinois campus.
- Construction begins in spring 2026, with operations expected in 2029 and 300 new hires planned.
AbbVie has announced a $380 million investment to construct two new active pharmaceutical ingredient (API) manufacturing facilities at its North Chicago, Illinois campus. The facilities will integrate advanced manufacturing technologies and artificial intelligence to support production of next-generation neuroscience and obesity medications.
Construction is scheduled to begin in spring 2026, with both facilities expected to be fully operational in 2029. The company plans to hire 300 employees in North Chicago, including engineers, scientists, manufacturing operators, and lab technicians to support the expansion.
“By strengthening our U.S. manufacturing capabilities, we are well-positioned to support our investment in innovation and enhance our ability to deliver next-generation medicines to patients.”
Robert A. Michael, chairman and chief executive officer of AbbVie
The investment forms part of AbbVie’s previously announced $100 billion commitment to U.S. R&D and capital investments over the next decade.
AbbVie stated that active pharmaceutical ingredient manufacturing involves producing the active components responsible for a medicine’s therapeutic effects. In September 2025, the company broke ground on a new chemical synthesis facility to return API production for select neuroscience, immunology, and oncology products from Europe and Asia to the U.S. The company employs approximately 29,000 people in the U.S., including more than 6,000 at its manufacturing sites, and more than 11,500 in Illinois.
